Pfizer Global Medical Grants – Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada – RFP Wave 2

Well-being, Health and Biomedical Discovery


Academic Unit: inquire with unit

Memorial Deadline: Wednesday 27th, September 2023

External Deadline: Monday 2nd, October 2023


Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an expert review panel (ERP) to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program. An ISR grant request cannot be submitted for a study that has already commenced and was not originally supported by Pfizer.

Date Wave 2 Funding Round RFP Issued: June 29, 2023

Geographic Scope: Canada

Clinical Area: Transthyretin Amyloid Cardiomyopathy

Link to full RFP: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research in Canada

Application Due Date: October 2, 2023

Specific Area of Interest: Pfizer is interested in supporting proposals that advance our understanding of the basic science and early diagnosis and treatment of ATTR cardiac amyloidosis through research. See Area of Interest section of RFP for further details.

Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to Amanda Stein, Grant Officer ( or interim alternate Grant Officer, Jackie Waldrop (

Funding Sources

Pfizer Inc

This opportunity was posted by: RGCS

Last modified: July 19, 2023